China
Africa
Explore chapters and articles related to this topic
Non-erythematous lesions
Published in Richard Ashton, Barbara Leppard, Differential Diagnosis in Dermatology, 2021
Richard Ashton, Barbara Leppard
This is a pox virus infection of the skin usually affecting children. Small 1–5 mm white or pink umbilicated papules are found anywhere on the skin and there may be few or many. They can become inflamed and red in colour. They last 6–24 months and then disappear spontaneously. In children with atopic eczema, they may be extensive particularly at the sites of the eczema. Isolated lesions in adults can be confused with a basal cell carcinoma.
Malignant diseases of the skin
Published in Rashmi Sarkar, Anupam Das, Sumit Sethi, Concise Dermatology, 2021
Anupam Das, Yasmeen Jabeen Bhat
Pathogenesis: Most lesions of basal cell carcinoma are due to chronic solar exposure and UVR damage, as they occur on light-exposed sites in photodamaged subjects. However, a larger proportion occurs in younger, non-light-exposed, non-photodamaged subjects than solar keratoses or other forms of NMSC. The explanation for this is uncertain.
Malignant disease of the skin
Published in Ronald Marks, Richard Motley, Common Skin Diseases, 2019
Most lesions of basal cell carcinoma are due to chronic solar exposure and UVR damage, as they occur on light-exposed sites in photodamaged subjects. However, a larger proportion occurs in younger, non-light-exposed, non-photodamaged subjects than solar keratoses or other forms of NMSC. The explanation for this is uncertain.
Accidental discovery of metastasized basal cell carcinoma
Published in Acta Chirurgica Belgica, 2022
Hanne Verberght, Thomas Schok, Siebe Wouda, Frits Aarts
The patient was admitted to the internal medicine department and had a consultation with general surgery. A normocytic anemia caused by chronic illness and type 2 diabetes was newly discovered upon admission. Histopathological investigation of the biopsy specimens from the lesion confirmed the diagnosis of solid growing basal cell carcinoma. An additional CT scan (thorax/abdomen/pelvis) showed a pathological fracture of the sacrum, a lung lesion in the right lower lobe (20 mm), and two liver lesions (8 and 21 mm). Bone biopsies confirmed the suspicion of metastatic basal cell carcinoma (Figure 2). Solid growing BCC with liver, lung, and bone metastases was diagnosed. The histology images confirmed the diagnosis of BCC as BerEp4 and cytokeratin 7 immunohistology were positive. In this case, p40 was also positive, which may indicate the development of squamous cell carcinoma (SCC). However, in SCC, BerEp4 and cytokeratin 7 immunohistology are negative.
A retrospective study comparing different injection approaches of 5-aminolevulinic acid in patients with non-melanoma skin cancer
Published in Journal of Dermatological Treatment, 2022
Weihong Zhao, Jun Wang, Ying Zhang, Baoyong Zheng
Nowadays incidences of skin cancer are increased in the world because of ultraviolet radiation, ozone depletion, and the other several factors (1). Consumption of caffeinated drinks reduces non-melanoma skin cancer in the Chinese population but the rate of non-melanoma skin cancer is highest in the Chinese population among the Asia-pacific because of Fitzpatrick skin types III (darker white skin) and IV (light brown skin) of the Chinese population (2). Most of the skin cancer is developed from the epidermis. From the basal cells and near the epidermis-dermis junction, the basal cell carcinoma (the non-melanoma skin cancer) is developed. It is the most common type of skin cancer. Also, from keratinocytes, the squamous cell carcinoma (the non-melanoma skin cancer) is developed which is the second most common skin cancer, and from the basal intercellular melanocytes, the melanoma skin cancer is developed and is the third most common skin cancer (3). The majority of the non-melanoma skin cancer are basal cell and squamous cell carcinomas in a ratio of approximately 4:1. Besides that, a wide variety of additional nonmelanoma skin tumors occurred from the other cells present in skin, for example, lymphocytes, Merkel cells, vascular endothelial cells, mesenchymal stromal cells, and cells forming the adnexal structures. These cancers are quite rare compared to basal cell and squamous cell carcinomas (4).
Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study
Published in Scandinavian Journal of Gastroenterology, 2020
Jonathan R. White, Said Din, Richard J. M. Ingram, Stephen Foley, Mohammad Aftab Alam, Richard Robinson, Rodric Francis, Emily Tucker, Mustafa Jalal, David Elphick, Edmond Atallah, Anthony Norman, Muhammad Amin, Aamir Sajjad, Nicola Heggs, Simon Meadowcroft, Gordon W. Moran
Patients (53%) had at least one hospital admission in the 12 months preceding vedolizumab commencement. This reduced to 30% during the observation period. The mean rate of IBD-related hospital admissions prior to vedolizumab initiation per patient per year for CD and UC was 1.0 (IQR 0–1.0) and 0.9 (IQR 0–2.0), respectively. Following vedolizumab initiation, median rate of hospitalisation for CD and UC were 1.0 (IQR 0–1.0) and 1.0 (IQR 0–1.0), respectively. Twenty-six patients had IBD related surgery (12 patients with CD and 14 patients with UC) during the observation period after initiation of vedolizumab. Four of these patients had two surgical procedures. Overall, 12 adverse events were recorded in patients receiving vedolizumab during the study observation period. The most common was intolerance of vedolizumab (n = 5) (Table 4). About 9% of patients were admitted with infections, with respiratory tract infections being the most common. Three patients were diagnosed with a malignancy during the observation period. One patient was diagnosed with basal cell carcinoma and treated with surgery. They received 14 doses of vedolizumab which was later stopped due to loss of response. Another patient who received four doses of vedolizumab (which was later stopped due to non-response) was diagnosed with acute myeloid leukaemia and was started on chemotherapy. The final patient underwent a prostatectomy for prostate cancer. The vedolizumab was continued for more than 12 months by the end of the observation period.